{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T23:23:16Z","timestamp":1763767396207,"version":"build-2065373602"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005992","name":"Ministry of Education and Science","doi-asserted-by":"publisher","award":["D01-278\/05.10.2020"],"award-info":[{"award-number":["D01-278\/05.10.2020"]}],"id":[{"id":"10.13039\/501100005992","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ejps.2022.106249","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T23:24:41Z","timestamp":1656545081000},"page":"106249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Peptide-based targeted cancer therapeutics: Design, synthesis and biological evaluation"],"prefix":"10.1016","volume":"176","author":[{"given":"Iwan","family":"Iwanov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Montesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irini","family":"Doytchinova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armen","family":"Sargsyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgi","family":"Momekov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8099-7132","authenticated-orcid":false,"given":"Silvia","family":"Panseri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia","family":"Naydenova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2022.106249_bib0056","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2147\/VHRM.S108874","article-title":"Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance","volume":"13","author":"Aghel","year":"2017","journal-title":"Vasc Health Risk Manag."},{"issue":"3","key":"10.1016\/j.ejps.2022.106249_bib0002","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/bip.10257","article-title":"Therapeutic cancer targeting peptides","volume":"66","author":"Aina","year":"2002","journal-title":"Biopolymers"},{"issue":"49","key":"10.1016\/j.ejps.2022.106249_bib0042","doi-asserted-by":"crossref","first-page":"5690","DOI":"10.1038\/sj.onc.1203926","article-title":"Development of inhibitors for protein tyrosine kinases","volume":"19","author":"Al-Obeidi","year":"2000","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.ejps.2022.106249_bib0046","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/(SICI)1097-0282(1998)47:3<197::AID-BIP2>3.0.CO;2-H","article-title":"Protein tyrosine kinases: structure, substrate specificity, and drug discovery","volume":"47","author":"Al-Obeidi","year":"1998","journal-title":"Pept. Sci."},{"key":"10.1016\/j.ejps.2022.106249_bib0007","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc903","article-title":"Ligand-targeted therapeutics in anticancer therapy","volume":"2","author":"Allen","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"6835","key":"10.1016\/j.ejps.2022.106249_bib0034","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/35077225","article-title":"Oncogenic kinase signalling","volume":"411","author":"Blume-Jensen","year":"2001","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.ejps.2022.106249_bib0017","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/psc.717","article-title":"Current strategies for the development of peptide-based anti-cancer therapeutics","volume":"11","author":"Borghouts","year":"2005","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.ejps.2022.106249_bib0087","doi-asserted-by":"crossref","unstructured":"Chandra, D.; Tang, D.G. Detection of apoptosis in cell-free systems. In: Apoptosis, Erhardt, P., Toth A., Eds Humana Press, Totowa, NJ, 2009, 559, 65-75.","DOI":"10.1007\/978-1-60327-017-5_5"},{"issue":"4","key":"10.1016\/j.ejps.2022.106249_bib0035","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrd773","article-title":"Protein kinases-the major drug targets of the twenty-first century?","volume":"1","author":"Cohen","year":"2002","journal-title":"Nat. Rev. Drug Discov"},{"issue":"139","key":"10.1016\/j.ejps.2022.106249_bib0079","doi-asserted-by":"crossref","first-page":"re6","DOI":"10.1126\/scisignal.3139re6","article-title":"ABL tyrosine kinases: evolution of function, regulation, and specificity","volume":"3","author":"Colicelli","year":"2010","journal-title":"Sci. Signal."},{"issue":"9","key":"10.1016\/j.ejps.2022.106249_bib0026","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/annonc\/mdm058","article-title":"Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy","volume":"18","author":"Cornelio","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejps.2022.106249_bib0082","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJM200101113440207","article-title":"Brain tumors","volume":"344","author":"DeAngelis","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ejps.2022.106249_bib0050","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2022.106249_bib0033","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jprot.2009.01.002","article-title":"Human defensins as cancer biomarkers and antitumour molecules","volume":"72","author":"Droin","year":"2009","journal-title":"J. Proteomics"},{"issue":"5","key":"10.1016\/j.ejps.2022.106249_bib0043","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr\u2013Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat. Med."},{"issue":"14","key":"10.1016\/j.ejps.2022.106249_bib0044","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejps.2022.106249_bib0090","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nbt.1513","article-title":"Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy","volume":"27","author":"Du","year":"2009","journal-title":"Nat. Biotechnol."},{"issue":"21","key":"10.1016\/j.ejps.2022.106249_bib0022","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.2174\/138161209788682253","article-title":"Peptide inhibitors targeting protein kinases","volume":"15","author":"Eldar-Finkelman","year":"2009","journal-title":"Curr. Pharm. Des."},{"issue":"9","key":"10.1016\/j.ejps.2022.106249_bib0029","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/12469","article-title":"Anti-cancer activity of targeted pro-apoptotic peptides","volume":"5","author":"Ellerby","year":"1999","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.ejps.2022.106249_bib0001","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1042\/BST0350780","article-title":"Tumour-homing peptides: tools for targeting, imaging and destruction","volume":"35","author":"Enb\u00e4ck","year":"2007","journal-title":"Biochem. Soc. Trans"},{"issue":"5-6","key":"10.1016\/j.ejps.2022.106249_bib0053","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/1947601912458586","article-title":"Activation of Abl family kinases in solid tumors","volume":"3","author":"Ganguly","year":"2012","journal-title":"Genes Cancer"},{"year":"2022","series-title":"GOLD Suite v5.2.2.2","key":"10.1016\/j.ejps.2022.106249_bib0062"},{"issue":"14","key":"10.1016\/j.ejps.2022.106249_bib0047","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM200104053441409","article-title":"Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Goldman","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2022.106249_bib0051","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0140-6736(00)02029-8","article-title":"Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia","volume":"355","author":"Goldman","year":"2000","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ejps.2022.106249_bib0052","first-page":"758","volume":"10","author":"Goodsell","year":"2005","journal-title":"The Onkologist"},{"issue":"8","key":"10.1016\/j.ejps.2022.106249_bib0078","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3563","article-title":"Role of ABL family kinases in cancer: from leukemia to solid tumors","author":"Greuber","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejps.2022.106249_bib0088","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/35037710","article-title":"The biochemistry of apoptosis","volume":"407","author":"Hengartner","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ejps.2022.106249_bib0031","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.bbamem.2007.11.008","article-title":"Studies on anticancer activities of antimicrobial peptides","volume":"1778","author":"Hoskin","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"issue":"3","key":"10.1016\/j.ejps.2022.106249_bib0040","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0092-8674(00)81872-3","article-title":"Oncoprotein networks","volume":"88","author":"Hunter","year":"1997","journal-title":"CellCell"},{"year":"2022","series-title":"HyperChem 8.0.6","key":"10.1016\/j.ejps.2022.106249_bib0060"},{"issue":"1","key":"10.1016\/j.ejps.2022.106249_bib0084","first-page":"414","article-title":"Antiproliferative effects of imatinib mesylate on ZR751 and MDAMB231 cell lines via PDGFR\u03b2, PDGFBB, cKit and SCF expression","volume":"42","author":"Kadivar","year":"2018","journal-title":"Int. J. Mol. Med."},{"issue":"9","key":"10.1016\/j.ejps.2022.106249_bib0024","first-page":"1","article-title":"Cancer therapeutics-opportunities, challenges and advances in drug delivery","volume":"1","author":"Kakde","year":"2011","journal-title":"J. Appl. Pharm. Sci"},{"key":"10.1016\/j.ejps.2022.106249_bib0086","doi-asserted-by":"crossref","first-page":"62214","DOI":"10.1039\/C5RA08501B","article-title":"Preparation of imatinib base loaded human serum albumin for application in the treatment of glioblastoma","volume":"5","author":"Kamali","year":"2015","journal-title":"RSC Adv."},{"issue":"4","key":"10.1016\/j.ejps.2022.106249_bib0019","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/jcb.21712","article-title":"Novel anti-angiogenic peptides derived from ELR-containing CXC chemokines","volume":"104","author":"Karagiannis","year":"2008","journal-title":"J. Cell. Biochem."},{"issue":"4","key":"10.1016\/j.ejps.2022.106249_bib0077","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/BF02931985","article-title":"Peptide Amidation: Production of Peptide Hormones in vivo and in vitro","volume":"6","author":"Kim","year":"2001","journal-title":"Biotechnol. Bioprocess Eng."},{"issue":"3","key":"10.1016\/j.ejps.2022.106249_bib0066","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood.V56.3.344.344","article-title":"Human myeloid leukemia cell lines: a review","volume":"56","author":"Koeffler","year":"1980","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ejps.2022.106249_bib0069","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1365-2141.1999.01700.x","article-title":"BCR-ABL influences the antileukaemic efficacy of alkylphosphocholines","volume":"107","author":"Konstantinov","year":"1999","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejps.2022.106249_bib0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bmc.2004.09.009","article-title":"\u03b2-Peptides as inhibitors of protein-protein interactions","volume":"13","author":"Kritzer","year":"2005","journal-title":"Bioorg. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejps.2022.106249_bib0011","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.3390\/ijms19092714","article-title":"Peptides as therapeutic agents for inflammatory-related diseases","volume":"19","author":"La Manna","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejps.2022.106249_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113547","article-title":"Cyclic mimetics of kinase-inhibitory region of Suppressors of Cytokine Signaling 1: progress toward novel anti-inflammatory therapeutics","volume":"221","author":"La Manna","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejps.2022.106249_bib0045","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1399-3011.1995.tb01323.x","article-title":"Identification and characterization of a novel synthetic peptide substrate specific for Src-family protein tyrosine kinases","volume":"45","author":"Lam","year":"1995","journal-title":"Int. J. Pept. Protein Res."},{"issue":"1","key":"10.1016\/j.ejps.2022.106249_bib0071","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1083\/jcb.123.1.7","article-title":"Nuclear events of apoptosis in vitro in cell-free mitotic extracts: a model system for analysis of the active phase of apoptosis","volume":"123","author":"Lazebnik","year":"1993","journal-title":"J. Cell Biol."},{"issue":"3","key":"10.1016\/j.ejps.2022.106249_bib0055","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.leukres.2006.08.011","article-title":"Late onset aplastic anemia during treatment of chronic myeloid leukemia with imatinib mesylate","volume":"31","author":"LeMarbre","year":"2007","journal-title":"Leuk. Res."},{"issue":"5","key":"10.1016\/j.ejps.2022.106249_bib0091","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.3171\/2018.12.JNS182926","article-title":"Characterizing tumor invasiveness of glioblastoma using multiparametric magnetic resonance imaging","volume":"132","author":"Li","year":"2019","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.ejps.2022.106249_bib0073","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nprot.2007.30","article-title":"In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro","volume":"2","author":"Liang","year":"2007","journal-title":"Nat. Protoc."},{"issue":"6","key":"10.1016\/j.ejps.2022.106249_bib0063","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10822-012-9551-4","article-title":"Pose prediction and virtual screening performance of GOLD scoring functions in a standardized test","volume":"26","author":"Liebeschuetz","year":"2012","journal-title":"J. Comput. Aided Mol. Des."},{"issue":"3","key":"10.1016\/j.ejps.2022.106249_bib0085","first-page":"789","article-title":"Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016)","volume":"31","author":"Lo","year":"2011","journal-title":"Anticancer Res."},{"issue":"11","key":"10.1016\/j.ejps.2022.106249_bib0083","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1101\/gad.891601","article-title":"Malignant glioma: genetics and biology of a grave matter","volume":"15","author":"Maher","year":"2001","journal-title":"Genes Dev."},{"issue":"14","key":"10.1016\/j.ejps.2022.106249_bib0070","doi-asserted-by":"crossref","first-page":"e00217","DOI":"10.1128\/JVI.00298-17","article-title":"Disparate contributions of human retrovirus capsid subdomains to Gag-Gag oligomerization, virus morphology, and particle biogenesis","volume":"91","author":"Martin","year":"2017","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.ejps.2022.106249_bib0021","first-page":"14","article-title":"Peptide inhibitors of protein-protein interactions: from rational design to the clinic","volume":"28","author":"Mochly-Rosen","year":"2010","journal-title":"Chim. Oggi \u2013 Chem. Today"},{"key":"10.1016\/j.ejps.2022.106249_bib0068","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"issue":"5","key":"10.1016\/j.ejps.2022.106249_bib0037","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.copbio.2006.08.002","article-title":"Peptides mediating interaction networks: new leads at last","volume":"17","author":"Neduva","year":"2006","journal-title":"Curr. Opin. Biotechnol"},{"key":"10.1016\/j.ejps.2022.106249_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-59745-419-3_1","article-title":"Peptide-based drug design: here and now","volume":"494","author":"Otvos","year":"2008","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejps.2022.106249_bib0008","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc1891","article-title":"Immunotoxin therapy of cancer","volume":"6","author":"Pastan","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejps.2022.106249_bib0041","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1615\/CritRevOncog.v7.i5-6.20","article-title":"Protein phosphorylation and dephosphorylation in physiologic and oncologic processes","volume":"7","author":"Patarca","year":"1996","journal-title":"Crit. Rev. Oncog."},{"issue":"10","key":"10.1016\/j.ejps.2022.106249_bib0072","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1172\/JCI6800","article-title":"Prevention of osteocyte and osteo-blast apoptosis by bisphosphonates and calcitonin","volume":"104","author":"Plotkin","year":"1999","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.ejps.2022.106249_bib0049","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/PPO.0000000000000165","article-title":"The role of new tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"22","author":"Pophali","year":"2016","journal-title":"Cancer J."},{"issue":"8","key":"10.1016\/j.ejps.2022.106249_bib0006","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/nbt1320","article-title":"Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting","volume":"25","author":"Qiu","year":"2007","journal-title":"Nat. Biotechnol."},{"issue":"5-6","key":"10.1016\/j.ejps.2022.106249_bib0058","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/1947601912462126","article-title":"The Ins and Outs of Bcr-Abl inhibition","volume":"3","author":"Reddy","year":"2012","journal-title":"Genes Cancer"},{"issue":"2","key":"10.1016\/j.ejps.2022.106249_bib0009","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/107327480200900207","article-title":"Future of monoclonal antibodies in the treatment of hematologic malignancies","volume":"9","author":"Reff","year":"2002","journal-title":"Cancer Control"},{"issue":"6","key":"10.1016\/j.ejps.2022.106249_bib0038","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.molcel.2005.10.030","article-title":"The role of docking interactions in mediating signaling input, output, and discrimination in the yeast MAPK network","volume":"20","author":"Remenyi","year":"2005","journal-title":"Mol. Cell"},{"issue":"6","key":"10.1016\/j.ejps.2022.106249_bib0039","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.sbi.2006.10.008","article-title":"Docking interactions in protein kinase and phosphatase networks","volume":"16","author":"Remenyi","year":"2006","journal-title":"Curr. Opin. Struct. Biol"},{"key":"10.1016\/j.ejps.2022.106249_bib0032","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1590\/S0001-37652009000300015","article-title":"Antifungal and antitumor models of bioactive protective peptides","volume":"81","author":"Rodrigues","year":"2009","journal-title":"An. Acad. Bras. Cienc."},{"issue":"8","key":"10.1016\/j.ejps.2022.106249_bib0018","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.2174\/138920111796117300","article-title":"Anti-angiogenic peptides for cancer therapeutics","volume":"12","author":"Rosca","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.ejps.2022.106249_bib0057","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, present, and future of Bcr-Abl inhibitors: from chemical development to clini-cal efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.ejps.2022.106249_bib0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165349","article-title":"In silico generation of peptides by replica exchange Monte Carlo: docking-based optimization of Maltose-binding-protein ligands","volume":"11","author":"Russo","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ejps.2022.106249_bib0089","first-page":"25","article-title":"An update to DNA ladder assay for apoptosis detection","volume":"5","author":"Saadat","year":"2015","journal-title":"Bioimpacts"},{"issue":"2","key":"10.1016\/j.ejps.2022.106249_bib0036","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0962-8924(01)02207-3","article-title":"Insulin signaling pathways in time and space","volume":"12","author":"Saltiel","year":"2002","journal-title":"Trends Cell Biol."},{"issue":"9","key":"10.1016\/j.ejps.2022.106249_bib0076","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra013339","article-title":"Imatinib mesylate\u2014a new oral targeted therapy","volume":"346","author":"Savage","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2022.106249_bib0048","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ejps.2022.106249_bib0028","doi-asserted-by":"crossref","first-page":"801","DOI":"10.18388\/abp.2006_3309","article-title":"Antitumor effect of RGD-4C-GG-D(KLAKLAK)2 peptide in mouse B16(F10) melanoma model","volume":"53","author":"Smolarczyk","year":"2006","journal-title":"Acta Biochim. Pol."},{"issue":"8","key":"10.1016\/j.ejps.2022.106249_bib0027","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/ijc.25192","article-title":"Regulation of HER expression and transactivation in human prostate cancer cells by a targeted cytotoxic bombesin analog (AN-215) and a bombesin antagonist (RC-3095)","volume":"127","author":"Sotomayor","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejps.2022.106249_bib0016","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1021\/cen-v089n022.p013","article-title":"Improving peptides","volume":"89","author":"Thayer","year":"2011","journal-title":"Chem. Eng. News."},{"key":"10.1016\/j.ejps.2022.106249_bib0013","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/967347","article-title":"Cancer treatment using peptides: current therapies and future prospects","volume":"2012","author":"Thundimadathil","year":"2012","journal-title":"J. Amino Acids"},{"issue":"5","key":"10.1016\/j.ejps.2022.106249_bib0023","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1158\/1535-7163.MCT-04-0213","article-title":"Antigene peptide nucleic acid specifically inhibits MYCN expression in human neuroblastoma cells leading to cell growth inhibition and apoptosis","volume":"4","author":"Tonelli","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejps.2022.106249_bib0064","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"Software News and Update AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejps.2022.106249_bib0012","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/nar\/gku892","article-title":"CancerPPD: a database of anticancer peptides and proteins","volume":"43","author":"Tyagi","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejps.2022.106249_bib0004","first-page":"495","volume":"125","author":"Vardanyan","year":"2016"},{"issue":"1-2","key":"10.1016\/j.ejps.2022.106249_bib0003","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.drudis.2009.10.009","article-title":"Synthetic therapeutic peptides: science and market","volume":"15","author":"Vlieghe","year":"2010","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejps.2022.106249_bib0014","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.drudis.2009.10.009","article-title":"Synthetic therapeutic peptides: science and market","volume":"15","author":"Vlieghe","year":"2010","journal-title":"Drug Discov. Today"},{"issue":"6","key":"10.1016\/j.ejps.2022.106249_bib0093","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.3390\/ijms21061932","article-title":"Tumor Cell Invasion in Glioblastoma","volume":"21","author":"Vollmann-Zwerenz","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"14","key":"10.1016\/j.ejps.2022.106249_bib0067","first-page":"3192","article-title":"Establishment and molecular characterization of a novel leukemic cell line with Philadelphia chromosome expressing p230 BCR\/ABL fusion protein","volume":"55","author":"Wada","year":"1995","journal-title":"Cancer Res."},{"issue":"5689","key":"10.1016\/j.ejps.2022.106249_bib0030","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1126\/science.1099191","article-title":"Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix","volume":"305","author":"Walensky","year":"2004","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.ejps.2022.106249_bib0054","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.trecan.2015.07.004","article-title":"The emerging role of ABL kinases in solid tumors","volume":"1","author":"Wang","year":"2015","journal-title":"Trends Cancer"},{"issue":"12","key":"10.1016\/j.ejps.2022.106249_bib0074","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","article-title":"AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL","volume":"94","author":"Weisberg","year":"2006","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.ejps.2022.106249_bib0075","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41416-019-0505-7","article-title":"Correction: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL","volume":"121","author":"Weisberg","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"Database issue","key":"10.1016\/j.ejps.2022.106249_bib0061","doi-asserted-by":"crossref","first-page":"D668","DOI":"10.1093\/nar\/gkj067","article-title":"DrugBank: a comprehensive resource for in silico drug discovery and exploration","volume":"34","author":"Wishart","year":"2006","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"10.1016\/j.ejps.2022.106249_bib0080","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/metabo10050173","article-title":"Evaluation of MDA-MB-468 cell culture media analysis in predicting triple-negative breast cancer patient sera metabolic profiles","volume":"10","author":"Wojtowicz","year":"2020","journal-title":"Metabolites"},{"issue":"5","key":"10.1016\/j.ejps.2022.106249_bib0092","doi-asserted-by":"crossref","first-page":"e64588","DOI":"10.1371\/journal.pone.0064588","article-title":"Synergistic inhibition of survival, proliferation, and migration of U87 cells with a combination of LY341495 and Iressa","volume":"8","author":"Yelskaya","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejps.2022.106249_bib0081","doi-asserted-by":"crossref","first-page":"6519","DOI":"10.2147\/OTT.S105716","article-title":"Novel therapeutic strategies for patients with triple-negative breast cancer","volume":"9","author":"Zhang","year":"2016","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.ejps.2022.106249_bib0025","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.3390\/md9101840","article-title":"Antitumor peptides from marine organisms","volume":"9","author":"Zheng","year":"2011","journal-title":"Mar. Drugs"},{"issue":"1","key":"10.1016\/j.ejps.2022.106249_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Sig. Transduct. Target Ther."},{"key":"10.1016\/j.ejps.2022.106249_bib0059","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1747-0285.2010.01054.x","article-title":"Structural mechanism of the pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance","volume":"77","author":"Zhou","year":"2011","journal-title":"Chem. Biol. Drug Des."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098722001348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098722001348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:02:49Z","timestamp":1760529769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098722001348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":93,"alternative-id":["S0928098722001348"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2022.106249","relation":{},"ISSN":["0928-0987"],"issn-type":[{"type":"print","value":"0928-0987"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peptide-based targeted cancer therapeutics: Design, synthesis and biological evaluation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2022.106249","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106249"}}